Rahul Gandhi attacks PM Modi on GDP, rising unemployment, vaccine shortage

Congress leader Rahul Gandhi on Tuesday attacked Prime Minister Narendra Modi over the adverse GDP and unemployment figures and raised the issue of "shortage" of drugs for treating black fungus

Rahul Gandhi
Press Trust of India New Delhi
2 min read Last Updated : Jun 01 2021 | 4:24 PM IST

Congress leader Rahul Gandhi on Tuesday attacked Prime Minister Narendra Modi over the adverse GDP and unemployment figures and raised the issue of "shortage" of drugs for treating black fungus.

"PM's hall of shame - Minimum GDP, Maximum Unemployment," he said on Twitter and shared a graph showing a rise in unemployment among the youth since 2014.

His remarks came a day after data released by the National Statistical Office (NSO) showed that India's economy contracted by 7.3 percent in the fiscal year ended March 2021 after the growth rate picked up in the fourth quarter, just before the world's worst outbreak of coronavirus infections hit the country.

The gross domestic product (GDP) in Asia's third-largest economy grew by 1.6 percent in the January-March period, up from 0.5 percent in the previous quarter when India began pulling out of a steep pandemic-induced recession in the earlier six months.

Gandhi also posed questions to the central government on mucormycosis or "black fungus epidemic".

"What is being done about the shortage of drug Amphotericin B? What is the procedure for helping the patient get this medicine," he said on Twitter.

"Instead of providing treatment, why is the Modi government embroiling the public in formalities," he also asked, but did not elaborate.

After thousands of cases of black fungus were reported among COVID-19 patients in the country, the Centre on May 20 urged all states and union territories to declare it as a notifiable disease under the Epidemic Diseases Act to ensure mandatory surveillance to tackle the "new challenge".

The government had said that the shortage of Amphotericin B shortage will be resolved soon as five more pharma companies have got new drug approval for producing it in India, in addition to the existing six pharma companies.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Rahul GandhiNarendra ModiGross domestic productUnemployment in IndiaCoronavirus Vaccine

First Published: Jun 01 2021 | 4:21 PM IST

Next Story